Adam Kadlec
Algemeen Directeur bij Rivermark Medical, Inc.
Profiel
Adam Kadlec is currently the President, Chief Executive Officer & Director at Rivermark Medical, Inc. and an Advisor at Golden Angels Investors LLC since 2018.
He completed his undergraduate and graduate degrees at the University of Wisconsin.
Actieve functies van Adam Kadlec
| Bedrijven | Functie | Begin |
|---|---|---|
Golden Angels Investors LLC
 Golden Angels Investors LLC Investment ManagersFinance Golden Angels Investors LLC (Golden Angels Investors) is a venture capital firm founded in 2002 by Timothy J Keane. The firm is headquartered in Brookfield, Wisconsin. | Consultant / Adviseur | 01-04-2018 |
Rivermark Medical, Inc.
 Rivermark Medical, Inc. Medical SpecialtiesHealth Technology The American company was founded by a practicing urologist with the aim of developing the preferred first-line device therapy for benign prostatic hyperplasia. The company's flagship product, the Flostent system, enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. Rivermark Medical plans to bring the Flostent system to market as their first product. The CEO of the company is Adam Kadlec. | Algemeen Directeur | 01-08-2021 |
Opleiding van Adam Kadlec
| University of Wisconsin | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Golden Angels Investors LLC
Golden Angels Investors LLC Investment ManagersFinance Golden Angels Investors LLC (Golden Angels Investors) is a venture capital firm founded in 2002 by Timothy J Keane. The firm is headquartered in Brookfield, Wisconsin. | Finance |
Rivermark Medical, Inc.
Rivermark Medical, Inc. Medical SpecialtiesHealth Technology The American company was founded by a practicing urologist with the aim of developing the preferred first-line device therapy for benign prostatic hyperplasia. The company's flagship product, the Flostent system, enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. Rivermark Medical plans to bring the Flostent system to market as their first product. The CEO of the company is Adam Kadlec. | Health Technology |
